{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:11:53Z","timestamp":1790719913165,"version":"4.1.0"},"reference-count":52,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2025,3,16]]},"DOI":"10.1080\/14737167.2024.2438631","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T09:02:51Z","timestamp":1733389371000},"page":"323-335","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness studies of brexu-cel for relapsed\/refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma: a systematic review"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6532-2439","authenticated-orcid":false,"given":"Asmita Priyadarshini","family":"Khatiwada","sequence":"first","affiliation":[{"name":"Auburn University","place":["Auburn, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-9188","authenticated-orcid":false,"given":"Ahmed Mostafa Ahmed","family":"Kamel","sequence":"additional","affiliation":[{"name":"Auburn University","place":["Auburn, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-8794","authenticated-orcid":false,"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[{"name":"University of Utah","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2327-224X","authenticated-orcid":false,"given":"Surachat","family":"Ngorsuraches","sequence":"additional","affiliation":[{"name":"Auburn University","place":["Auburn, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"e_1_3_7_3_1","unstructured":"National cancer institute [internet]. USA: Adult Acute Lymphoblastic Leukemia Treatment; 2023 [cited 2024 Jan 20]. Available from: https:\/\/www.cancer.gov\/types\/leukemia\/patient\/adult-all-treatment-pdq"},{"key":"e_1_3_7_4_1","unstructured":"American Cancer Society [Internet]. Key statistics for acute lymphocytic leukemia (ALL). 2024 [cited 2024 Jan 20]. Available from: https:\/\/www.cancer.org\/cancer\/types\/acute-lymphocytic-leukemia\/about\/key-statistics.html"},{"key":"e_1_3_7_5_1","unstructured":"Cancer.Net.[Internet]. Leukemia - acute lymphocytic - ALL: statistics: American Society of Clinical Oncology (ASCO). 2023 [cited 2024 Jan 20]. Available from: https:\/\/www.cancer.net\/cancer-types\/leukemia-acute-lymphocytic-all\/statistics"},{"key":"e_1_3_7_6_1","unstructured":"Cancer research [Internet].UK: acute lymphoblastic leukaemia. 2021 [cited 2024 Jan 20]. Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/acute-lymphoblastic-leukaemia-all\/about"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"e_1_3_7_8_1","volume-title":"StatPearls [internet]","author":"Lynch DT","year":"2023","unstructured":"Lynch DT, Koya S, Acharya U, et al. Mantle Cell Lymphoma. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Jan 20]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK536985\/#:~:text=Epidemiology-,Mantle%20cell%20lymphoma%20(MCL)%20is%20a%20rare%20subtype%20of%20B,60%20to%2070%20years%20old"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-019-0126-0"},{"key":"e_1_3_7_10_1","unstructured":"American Cancer Society [Internet]. Types of B-cell lymphoma. 2019 [cited 2024 Jan 20]. Available from: https:\/\/www.cancer.org\/cancer\/types\/non-hodgkin-lymphoma\/about\/b-cell-lymphoma.html"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.320"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004765"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32116"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8961"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15567"},{"key":"e_1_3_7_17_1","unstructured":"FDA[Internet]. TECARTUS (brexucabtagene autoleucel). 2023 [cited 2024 Jan 20] Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370"},{"key":"e_1_3_7_20_1","volume-title":"Red Book-Brexucabtagene autoleucel","author":"Micromedex","year":"2024","unstructured":"Micromedex. Red Book-Brexucabtagene autoleucel. Michigan, USA: Merative US L.P.; 2024 [cited 2024 Feb 10]."},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030164"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2215888"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2079317"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02201-6"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1894158"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.04.004"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01755-5"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1332\/174426410X482999"},{"key":"e_1_3_7_30_1","unstructured":"Calculator UI. Inflation calculator: coin news media group company. 2024 [cited 2024 Mar 14]. Available from: https:\/\/www.usinflationcalculator.com\/"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2015.1103185"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.008"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00812-6"},{"issue":"4","key":"e_1_3_7_34_1","first-page":"93","article-title":"Brexucabtagene Autoleucel (tecartus): acute lymphoblastic leukemia","volume":"3","author":"CADTH","year":"2023","unstructured":"CADTH. Brexucabtagene Autoleucel (tecartus): acute lymphoblastic leukemia. Can J Health Technol. 2023;3(4):93\u2013145. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2023\/PG0304-Tecartus-ALL.pdf","journal-title":"Can J Health Technol"},{"key":"e_1_3_7_35_1","unstructured":"NICE [Internet]. England. Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over [ID1494]. 2022 [cited 2024 Mar 11]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta893\/evidence\/appraisal-consultation-committee-papers-pdf-13064338333"},{"key":"e_1_3_7_36_1","unstructured":"NICE [Internet]. Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over [ID1494]. (UK); 2023 [cited 2024 Mar 11]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta893\/evidence\/final-appraisal-determination-committee-papers-pdf-13064338334"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00700.x"},{"key":"e_1_3_7_38_1","unstructured":"MSAC [Internet]. Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia. Australia; 2022 [cited 2024 Mar 11] Available from: http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/0C9197DC317F49F2CA258856001CDFC8\/$File\/1723%20Final%20PSD-%20Nov%202022_redacted.pdf"},{"key":"e_1_3_7_39_1","unstructured":"MSAC [Internet]. Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia. Australia; 2023 [cited 2024 Mar 11] Available from: http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/CCCB670A7221E361CA2589C1001957AB\/$File\/1723.1%20Final%20PSD%20-%20Nov2023%20(redacted).pdf"},{"key":"e_1_3_7_40_1","unstructured":"SMC [Internet]. Brexucabtagene autoleucel 0.4\u20132 \u00d7 108 cells dispersion for infusion (Tecartus\u00ae) Scotland. Scotland. 2023 [cited 2024 Mar 14]. Available from: https:\/\/www.scottishmedicines.org.uk\/media\/7869\/brexucabtagene-autoleucel-tecartus-final-sept-2023-for-website.pdf"},{"key":"e_1_3_7_41_1","unstructured":"NICE [Internet]. Ibrutinib for treating relapsed or refractory mantle cell lymphoma. (UK): NICE; 2016 [cited 2024 Mar 27] Available from: https:\/\/www.nice.org.uk\/guidance\/ta502\/documents\/committee-papers"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2021.135"},{"key":"e_1_3_7_43_1","unstructured":"NICE [Internet]. Ibrutinib for treating relapsed or refractory mantle cell lymphoma. (UK); 2018 [cited 2024 Mar 27] Available from: https:\/\/www.nice.org.uk\/guidance\/ta502\/resources\/ibrutinib-for-treating-relapsed -or-refractory-mantle-cell-lymphoma-pdf-82606716182725"},{"key":"e_1_3_7_44_1","unstructured":"NICE [Internet]. England. Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID1313]. 2020 [cited 2024 Mar 12] Available from: https:\/\/www.nice.org.uk\/guidance\/ta677\/evidence\/committee-papers-pdf-9016513021"},{"key":"e_1_3_7_45_1","unstructured":"NICE [Internet]. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma. (UK); 2021 [cited 2024 Mar 12] Available from: https:\/\/www.nice.org.uk\/guidance\/ta677\/chapter\/3-Committee-discussion"},{"key":"e_1_3_7_46_1","unstructured":"MSAC [Internet]. Australia. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma. 2023 [cited 2024 Mar 14: Available from: https:\/\/msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/A10E3D10B9DBC1F2CA258614002163DC\/$File\/1647%20Final%20PSD%20-%20updated%20with%20July%202023%20Addendum%20(redacted).pdf"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129829"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2021.135"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462323000326"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.07.008"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179269"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17746989"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.001"},{"key":"e_1_3_7_54_1","first-page":"166","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia","volume":"17","author":"Paul S","year":"2019","unstructured":"Paul S, Rausch CR, Nasnas PE, et al. Treatment of relapsed\/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019;17:166\u2013175.","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2024.2438631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T05:41:19Z","timestamp":1740894079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2024.2438631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,16]]}},"alternative-id":["10.1080\/14737167.2024.2438631"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2024.2438631","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}